Novel decision algorithm to discriminate parkinsonism with combined blood and imaging biomarkers
Stephanie Mangesius, Sara Mariotto, Sérgio Ferrari, Sergiy Pereverzyev, Hannes Lerchner, Lukas Haider, Elke R. Gizewski, Gregor K. Wenning, Klaus Seppi, Markus Reindl, Werner Poewe
Abstract
INTRODUCTION: To determine an exploratory multimodal approach including serum NFL and MR planimetric measures to discriminate Parkinson's disease (PD), multiple system atrophy (MSA) and progressive supranuclear palsy (PSP). METHODS: MR planimetric measurements and NFL serum levels, with a mean time interval of 60 months relative to symptom onset, were assessed in a retrospective cohort of 11 progressive supranuclear palsy (PSP), 22 Parkinson's disease (PD), 16 multiple system atrophy (MSA) patients and 42 healthy controls (HC). A decision tree model to discriminate PD, PSP, and MSA was constructed using receiver operating characteristic curve analysis and Classification and Regression Trees algorithm. RESULTS: ) discriminated MSA from PSP at a cut-off value of 2.06. The combined overall diagnostic yield was an accuracy of 83.7% (95% CI 69.8-90.8%). CONCLUSION: We provide a clinically feasible decision algorithm which combines serum NFL levels and a planimetric MRI marker to differentiate PD, MSA and PSP with high diagnostic accuracy. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that the combination of serum NFL levels und MR planimetric measurements discriminates between PD, PSP and MSA.